Compare IONS & PINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IONS | PINS |
|---|---|---|
| Founded | 1989 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 12.0B |
| IPO Year | 1996 | 2019 |
| Metric | IONS | PINS |
|---|---|---|
| Price | $74.88 | $20.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 29 |
| Target Price | ★ $92.73 | $26.78 |
| AVG Volume (30 Days) | 1.6M | ★ 13.4M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.71 | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $4,221,767,000.00 |
| Revenue This Year | N/A | $14.48 |
| Revenue Next Year | $77.99 | $12.04 |
| P/E Ratio | ★ N/A | $33.65 |
| Revenue Growth | N/A | ★ 15.79 |
| 52 Week Low | $28.79 | $13.84 |
| 52 Week High | $86.74 | $39.93 |
| Indicator | IONS | PINS |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 67.33 |
| Support Level | $69.85 | $17.55 |
| Resistance Level | $77.08 | $27.86 |
| Average True Range (ATR) | 1.99 | 0.70 |
| MACD | 0.16 | 0.33 |
| Stochastic Oscillator | 45.01 | 88.17 |
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Pinterest is a social media platform with a focus on product and idea discovery. Pinterest users, or pinners, can leverage the platform as they go about gathering ideas on topics such as home improvement, fashion, cooking, and travel. The company has more than 500 million monthly active users, two thirds of whom are female. Pinterest generates revenue by selling digital ads on its platform. While the platform's user base spans the globe, the vast majority of its revenue stems from ads shown to North American users.